RA
ASND icon

Rosalind Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Rosalind Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,800
Closed -$2.12M – 34
2023
Q4 		$2.12M Buy
+16,800
New +$1.67M 1.74% 20

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Rosalind Advisors's ASND Position: Q1 2024 in Review

Rosalind Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 16,800 shares — an estimated $2.12M sold.

Rosalind Advisors first reported a position in ASND in Q4 2023 and held it in 1 quarter. The position peaked at $2.12M in Q4 2023. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

  • Rosalind Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
  • Rosalind Advisors sold 16,800 Ascendis Pharma A/S shares in Q1 2024, an estimated $2.12M.
  • Rosalind Advisors first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 1 quarter.
  • Rosalind Advisors's Ascendis Pharma A/S position peaked at $2.12M in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.